Studies with 8-azainosine, a cytotoxic nucleoside with antitumor activity.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001372:Aza Compounds / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D001375:Azaguanine / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000201:enzymology; D002460:Cell Line; D002478:Cells, Cultured; D004351:Drug Resistance; D006801:Humans; D007042:Hypoxanthines / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007288:Inosine / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use* / Q000031:analogs & derivatives; D007939:Leukemia L1210 / Q000188:drug therapy; D015122:Mercaptopurine / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental; D010430:Pentosyltransferases / Q000378:metabolism; D010770:Phosphotransferases / Q000378:metabolism; D011687:Purines / Q000378:metabolism
D000970:Antineoplastic Agents; D001372:Aza Compounds; D007042:Hypoxanthines; D007093:Imidazoles; D011687:Purines; C002869:8-azainosine; D007288:Inosine; D015122:Mercaptopurine; D010430:Pentosyltransferases; D010770:Phosphotransferases; D001375:Azaguanine